SOCM
SR One Capital Management Portfolio holdings
AUM
$461M
This Quarter Return
-19.37%
1 Year Return
+23.25%
3 Year Return
+188.96%
5 Year Return
–
10 Year Return
–
AUM
$319M
AUM Growth
+$319M
(-12%)
Cap. Flow
+$33.9M
Cap. Flow
% of AUM
10.62%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
9
New
3
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
ALMS
Alumis Inc. Common Stock
ALMS
|
$26.1M |
| 2 |
enGene Holdings
ENGN
|
$4.72M |
| 3 |
KALA BIO
KALA
|
$3.15M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Arcellx
ACLX
$3.85B
| $130M | 40.55% |
2,346,630
| – | – |
|
2
CRISPR Therapeutics
CRSP
$4.71B
| $56.7M | 17.74% |
1,048,951
| – | – |
|
3
ARS Pharmaceuticals
SPRY
$1.15B
| $34.1M | 10.69% |
4,012,903
| – | – |
|
|
ALMS
4
Alumis Inc. Common Stock
ALMS
$479M
| $26.1M | 8.16% |
+1,959,896
| New | +$26.1M |
|
5
Mineralys Therapeutics
MLYS
$1.03B
| $23.6M | 7.39% |
2,016,822
| – | – |
|
6
Design Therapeutics
DSGN
$315M
| $21.9M | 6.85% |
6,526,476
| – | – |
|
7
Nkarta
NKTX
$151M
| $19.7M | 6.17% |
3,333,333
| – | – |
|
|
8
enGene Holdings
ENGN
$236M
| $4.72M | 1.48% |
+500,000
| New | +$4.72M |
|
|
9
KALA BIO
KALA
$78.8M
| $3.15M | 0.98% |
+443,661
| New | +$3.15M |
|